RE: [CANSLIM] ACDO, SRA

From: "Rich Mau" <rmau@earthlink.net>
Subject: RE: [CANSLIM] ACDO, SRA
Date: Fri, 8 Mar 2002 10:50:47 -0800

Next Article (by Subject): RE: [CANSLIM] ACDO, SRA "Keith Williams"
Previous Article (by Subject): [CANSLIM] ACDO, SRA "Tim Fisher"
Next in Thread: RE: [CANSLIM] ACDO, SRA "Keith Williams"
Articles sorted by: [Date] [Author] [Subject]

This is a multi-part message in MIME format.

- ------=_NextPart_000_0042_01C1C68F.1AFD10A0
Content-Type: text/plain;
	charset="Windows-1252"
Content-Transfer-Encoding: 7bit

      [From Yahoo]
      Serono S.A., headquartered in Geneva, Switzerland, is a global
biotechnology company with six recombinant products on the market: Gonal-F,
Luveris, Ovidrel/Ovitrelle, Rebif, Serostim and Saizen (Rebif and Luveris
are not approved in the United States). In addition to reproductive health,
Serono has strong market positions in neurology, metabolism and growth. The
Company's research programs are focused on growing these businesses and on
establishing new therapeutic areas. Currently, there are 15 new molecules in
development. The Company operates in 45 countries, and its products are sold
in over 100 countries.
      More from Market Guide:



> -----Original Message-----
> From: owner-canslim@lists.xmission.com
> [mailto:owner-canslim@lists.xmission.com]On Behalf Of Tim Fisher
> Sent: Friday, March 08, 2002 9:46 AM
> To: canslim@mail.xmission.com
> Subject: [CANSLIM] ACDO, SRA
>
>
> Noticed the reason for ACDO's tumble this AM was SRA got approval for a
> drug that has a different distributor. Anyone know anything about SRA? It
> doesn't show up in my scans...
>
>
> Tim Fisher



- ------=_NextPart_000_0042_01C1C68F.1AFD10A0
Content-Type: text/html;
	charset="Windows-1252"
Content-Transfer-Encoding: quoted-printable

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD><TITLE></TITLE>
<META http-equiv=3DContent-Type content=3D"text/html; =
charset=3Dus-ascii">
<META content=3D"MSHTML 6.00.2713.1100" name=3DGENERATOR></HEAD>
<BODY>
<TABLE cellSpacing=3D0 cellPadding=3D2 border=3D0>
  <TBODY>
  <TR>
    <TD>
      <DIV>[From Yahoo]</DIV>
      <DIV>Serono S.A., headquartered in Geneva, Switzerland, is a =
global=20
      biotechnology company with six recombinant products on the market: =

      Gonal-F, Luveris, Ovidrel/Ovitrelle, Rebif, Serostim and Saizen =
(Rebif and=20
      Luveris are not approved in the United States). In addition to=20
      reproductive health, Serono has strong market positions in =
neurology,=20
      metabolism and growth. The Company's research programs are focused =
on=20
      growing these businesses and on establishing new therapeutic =
areas.=20
      Currently, there are 15 new molecules in development. The Company =
operates=20
      in 45 countries, and its products are sold in over 100=20
  countries.</DIV></TD></TR>
  <TR>
    <TD colSpan=3D2><SMALL><I>More from Market Guide</I>:=20
</SMALL></TD></TR></TBODY></TABLE><BR><BR>
<P><FONT size=3D2>&gt; -----Original Message-----<BR>&gt; From:=20
owner-canslim@lists.xmission.com<BR>&gt; [<A=20
href=3D"mailto:owner-canslim@lists.xmission.com">mailto:owner-canslim@lis=
ts.xmission.com</A>]On=20
Behalf Of Tim Fisher<BR>&gt; Sent: Friday, March 08, 2002 9:46 =
AM<BR>&gt; To:=20
canslim@mail.xmission.com<BR>&gt; Subject: [CANSLIM] ACDO,=20
SRA<BR>&gt;<BR>&gt;<BR>&gt; Noticed the reason for ACDO's tumble this AM =
was SRA=20
got approval for a<BR>&gt; drug that has a different distributor. Anyone =
know=20
anything about SRA? It<BR>&gt; doesn't show up in my=20
scans...<BR>&gt;<BR>&gt;<BR>&gt; Tim Fisher<BR></FONT></P></BODY></HTML>

- ------=_NextPart_000_0042_01C1C68F.1AFD10A0--


- -
- -To subscribe/unsubscribe, email "majordomo@xmission.com"
- -In the email body, write "subscribe canslim" or
- -"unsubscribe canslim".  Do not use quotes in your email.

Go to Jeff Salisbury LWGate Home Page.